How could the new subcutaneous induction regimen affect the Center for Devices and Radiological Health?
CDRH must oversee the on-body injector device used in Skyrizi's new regimen. The FDA's approval of the subcutaneous induction regimen for Skyrizi allows patients with moderate to severe Crohn's disease to start treatment at home. This new method relies on an on-body injector induction pack, which is a medical device. As the Center for Devices and Radiological Health (CDRH) is the division of the FDA responsible for regulating medical devices, the deployment of this new treatment pathway requires CDRH to maintain regulatory oversight of the injector pack's safety and performance.
- Effect
- Mild positive
- How direct
- Brind's reasoning
- When
- Right away
- The story
- Gone quiet
How it reaches Center for Devices and Radiological Health
-
The FDA approved a subcutaneous induction regimen of risankizumab (Skyrizi) for adults with moderate to severe Crohn’s disease. This approval expands the previous authorization, which was for an intravenous induction followed by subcutaneous maintenance. The new regimen allows patients to begin induction therapy at home using an on-body injector induction pack.
The full event1independent outlet -
The FDA approved the subcutaneous induction regimen of risankizumab for Crohn’s disease, which allows patients to start induction therapy at home. This new treatment method utilizes an on-body injector induction pack, a medical device that must be regulated by the Center for Devices and Radiological Health.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
center of the U.S. Food and Drug Administration
Everything about Center for Devices and Radiological Health
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- The FDA approved a subcutaneous induction regimen of risankizumab for adults with moderate to severe Crohn’s disease.healio.com
- The latest approval allows patients to start treatment from home with an on-body injector induction pack.healio.com
Why it matters
The approval of new drug delivery methods often necessitates regulatory adjustments for the associated hardware. For CDRH, this means expanding its oversight to ensure that the on-body injector pack meets stringent safety and efficacy standards required for home use. This regulatory function is critical to ensuring patient safety in advanced therapies.
This is part of a broader trend in pharmaceutical development where drugs are increasingly paired with sophisticated medical devices to improve patient convenience and treatment adherence. CDRH's role is to manage this intersection of drug and device technology within the U.S. healthcare system.
What we don't know yet
- What specific regulatory requirements does the on-body injector induction pack meet?
- How will the FDA monitor the long-term safety of the device when used in a home setting?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
Reporting
- healio.comOct 23
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.